Diamyd close to important milestone

Diamyd Medical announces today that 90 percent of the total 320 children and

adolescents with type 1 diabetes due to participate in the company's European

Phase III study with the diabetes vaccine Diamyd® have now been included and

have received injections of Diamyd® or placebo. The company expects all

participants to have been included in the study by November 2009.

Diamyd Medical is conducting a global Phase III program with the diabetes

vaccine Diamyd® comprising a study in nine countries in Europe and a study in

the US. In each study 320 children and adolescents aged 10-20 newly diagnosed

with type 1 diabetes will take part.

"We are now close to our first important milestone in the Phase III program,"

says Elisabeth Lindner, President and CEO of Diamyd Medical. "We expect the

study to be fully recruited by November 2009."

"The results will be analyzed during spring 2011, when all patients have

participated in the study for 15 months."

The purpose of the study is to investigate whether the Diamyd® vaccine can delay

or stop the break-down of beta cells in the pancreas and hence preserve the

body's own ability to control the blood sugar in patients newly diagnosed with

type 1 diabetes. This could in turn reduce the risk for acute and long-term

diabetic complications.

In the study, two thirds of participants are receiving the Diamyd® vaccine and

one third is receiving placebo (an inactive substance). The study is conducted

at 70 clinics in Europe.

As previously announced, the company is investing in accelerated patient

recruitment for the parallel US Phase III study with the diabetes vaccine

Diamyd® through recruitment campaigns and an increase in the number of

participating US pediatric diabetes clinics.

For more information, please contact:

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)

Phone: +46 8 661 0026

For pictures and press material, please contact:

Andreas Ericsson, Diamyd Medical AB (publ.)


Phone: +46 8 661 0026

About Diamyd Medical

Diamyd Medical is a Swedish diabetes company focusing on the development of

pharmaceuticals for the treatment of autoimmune diabetes and its complications.

The company's most advanced project is the GAD-based drug Diamyd® for type 1

diabetes. Phase III trials for this drug are in progress in both Europe and the

US. In addition, the company has initiated clinical studies in the US in the

area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS).

The company has also out-licensed the use of GAD for the treatment of

Parkinson's disease. The company currently has three clinical-phase products.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq

OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)

administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Further information is available on the company's website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities Markets

Act, the Swedish Financial Instruments Trading Act, or the requirements stated

in the listing agreements.

Diamyd Medical AB (publ.)

Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 661 00 26, Fax: +46

(0)8 661 63 68

E-mail: info@diamyd.com. VAT no: SE556530-142001.


  PDF version